Publications by authors named "A Loganayagam"
Article Synopsis
- Inflammatory bowel disease (IBD) patients often stop thiopurine therapy due to side effects or lack of response, prompting a study on the impact of measuring 6-thioguanine nucleotides (TGN) and thiopurine S-methyltransferase (TPMT) on treatment outcomes.
- The study involved 316 IBD patients across four medical centers in the Netherlands and the UK, with notable findings in TGN levels based on different TPMT genotypes and phenotypes.
- The results suggest that while TPMT measurements could be helpful at the start of treatment, routine TGN monitoring isn’t essential, as it did not correlate strongly with treatment-related issues.
Background: Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response. Its widespread use has been hampered due to concerns about nodular regenerative hyperplasia (NRH) of the liver. The aim of this study was to investigate the long-term efficacy and safety of low-dose TG therapy in IBD patients failing AZA and MP.
View Article and Find Full Text PDF